Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cellectar Biosciences, Inc. - Common Stock
(NQ:
CLRB
)
0.2908
+0.0098 (+3.49%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cellectar Biosciences, Inc. - Common Stock
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
January 12, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
December 10, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
November 18, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
November 14, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
November 12, 2024
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Cellectar Biosciences Inc. (NASDAQ: CLRB) Near Top of Volume Charts in Tuesday Trading
September 05, 2023
Via
Investor Brand Network
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.